Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01757691 · ClinicalTrials.gov registry record · Phase 2
Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01757691: Clinical Trial Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01757691 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01757691, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment
Primary Outcome
Due to early termination and low patient enrollment the primary outcome measure was not analyzed
Interventions
- DRUG Placebo
- DRUG Fingolimod 0.5mg/daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Why NCT01757691 stopped before completion
NCT01757691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01757691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01757691 about?
NCT01757691 is a clinical study titled "Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)". To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment
What is the current status of trial NCT01757691?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-08. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01757691?
The interventions under investigation include: Placebo (DRUG), Fingolimod 0.5mg/daily (DRUG).
Who is sponsoring clinical trial NCT01757691?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01757691's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia